Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorts will continue to come on board until we can give them a reason to go away. I know Martin is working hard to ramp up the Carebot for production, it's a process that takes time. I know we are all hopeful about the future of GCKO and support the company until we can squeeze the shorts and watch them squirm. That will be a good day! GLTA.
A hurricane feeding from the southern part of the gulf would slam the shoreline with the entire slick all at once. It would be like that commercial where the two dudes are sitting on the couch and get drenched with engine sludge.
Have you made contact with anybody from EVXA?
updated 1:22 a.m. ET, Fri., April 30, 2010
VENICE, La. - An oil spill that threatened to eclipse even the Exxon Valdez disaster spread out of control with a faint sheen washing ashore along the Gulf Coast Thursday night as fishermen rushed to scoop up shrimp and crews spread floating barriers around marshes.
The spill was bigger than imagined — five times more than first estimated — and closer. Faint fingers of oily sheen were reaching the Mississippi River delta, lapping the Louisiana shoreline in long, thin lines.
"It is of grave concern," David Kennedy of the National Oceanic and Atmospheric Administration, told The Associated Press. "I am frightened. This is a very, very big thing. And the efforts that are going to be required to do anything about it, especially if it continues on, are just mind-boggling."
http://www.msnbc.msn.com/id/36800673/ns/us_news-environment/
EVXA, BCLE, ACLH have found bottom and are consolidating, good time to get in before clean up start rolling in.
hopefully we can see a rebound after the conference call
Long term possibility...This catastrophe, not unlike how 911 opened up a whole new market for domestic secruity firms and technologies, will do the same thing for oil clean up. Every company in the oil business wil have to reach out and contract companies and follow stringent standards in regards to oil clean up plans. You know how our government works, under prepare, over compensate. These start up companies stand to fare very well over the course of the year (yes it will take that long to clean up this mess). This is just an opinion...I care less about a few days trades, but the discovery of new markets and long term revenue is interesting.
I like the MOMO. This has been kept down for too long. Looking forward to call on Friday.
Wait until the oil hits shore and the largest clean up EVER is underway.
Shake the tree - time to get some.
EVXA sets up to manage the 200,000 gallons a day that is spewing from the underground well. It is being reported that it could take months to control the leak. This will be the largest clean up effoirt ever and will utilize ever available technology and resource. EVXA is set up nice for this IMO.
EVXA - with huge upside as they now have cash and are can comnpete with their technology!
Watch the news tonight and the reports of this spill getting increasing worse!!!! This is just the beginning.
EVXA going crazy
Looking for extremely positive fallout from oil situation in gulf. Bio fuels will become a hot topic IMO.
They want your shares. hold out for another run up.
I think this will continue to move up.
EVXA - oil spill play
EnviroXtract, Inc. (EVXA) has developed an efficient technology to perform environmental remediation applications for oil spills and other toxic chemical
remediation applications which require a complete separation of hazardous or toxic chemicals from contaminated soil. The technology has proven capable of removing virtually 100% of oil from soil...is extremely energy efficient...leaves clean, dry tailings with no residual oil...requires no water, natural gas
, fossil fuels, or chemicals during processing...discharges no pollutants...and is capable of capturing carbon emissions in a closed vacuum processing system.
EnviroXtract will implement an aggressive schedule of testing its proprietary thermal process for extraction of various hazardous and toxic materials from soil samples. The Environmental Protection Agency (EPA) maintains a Toxic Release Inventory of 581 individually listed chemicals and 30 chemical categories which require removal and mitigation under federal regulations. Independent third-party analysis and verification will measure the effectiveness of the EXI thermal process in removing many of these toxic chemicals from soil samples. The results of these tests and subsequent analysis will be updated regularly on the EnviroXtract website, www.EnviroXtract.com. EnviroXtract plans to explore additional environmental remediation applications to enhance its business model.
This will continue to rise as the spill increases in severity. This trade could extend out over a long period and pps continually rising.
EVXA - exploding - +57% and rising
Nothng really new though huh?
I wonder how the recent oil spill in the gulf will turn heads toward alternative fuels that pose less of a threat to the environment. Good earnings report could explode this pps.
Hopefully that was shorts covering driving the pps down. Figures i just bought some other stock today and my other funds have not freed up or i would have bought .0135 all day long.
All we have is hope right now. Smiling would be nice!
IRBT came out with some solid earnings.
The more positive press about the robot industry has to be good right?
The company reported that it earned $6.2 million, or 24 cents per share, for the quarter. That's up from a loss of $1.8 million, or 7 cents per share, in the same quarter last year.
Revenue grew 67 percent to $95 million.
Analysts polled by Thomson Reuters on average expected the company to earn 4 cents per share on revenue of $83.8 million.
The company said its international home robot revenue more than doubled to $37 million during the quarter, and its government and industrial robot revenue rose 76 percent.
IRobot, based in Bedford, Mass., said it anticipates earning between 6 cents to 8 cents per share for the second quarter and 35 cent to 40 cents per share for the full year. Analysts expected the company to post a loss of 4 cents per share for the second quarter and a profit of 23 cents per share for the year.
IRobot shares fell 21 cents to close at $15.22. But shares rose $3.28, more than 21 percent, to $18.30 in after-hours trading.
Honestly, if it's at .016 or .014 it doesn't really matter because we are all banking on this being worth closer to .10 in the short term. I do recall buying some shares on drops prior to the big 600% move in December. Need some of that love again!
I'm a holder for over a year and still think this is gonna go, but promises and "gonna's" can not grow pps over an extended period of time. Need "pops" of breakthrough news to grow because during the "no news" periods, it will drift lower.
I'm all for buying opportunities, but I don't like seeing this drop.
Seeing good movement here. Somebody knows something????
The PR saying there will be contract PR's coming soon is not what will jump the stock...it's the actual PR explaining the signed contracts. Those who are getting nervous here are giving up their shares at low levels...patience.
Good buying today
ACTC - news out!
Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy De...
Date : 04/23/2010 @ 9:08AM
Source : Business Wire
Stock : Advanced Cell Technology, Inc. (ACTC)
Quote : 0.0917 0.0 (0.00%) @ 7:49AM
Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy De...
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt’s Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues. The studies were designed to address the FDA’s request for additional data on tumorigenicity and biodistribution. The Company believes that the data will support the FDA granting clearance for the Company to commence the SMD study in humans later this year. The studies were completed in conjunction with Sinclair Research, based in Columbia, Missouri, Charles River Labs, MPI and Althea Labs, which have been the company’s outside independent collaborators on both studies.
“We believe these animal studies demonstrate an excellent safety profile for our RPE cell therapy,” said William M. Caldwell IV, ACT’s Chairman & CEO . “We look forward to concluding our discussions with the FDA so that we can commence our study later this year.”
The Phase I trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the retinal pigment epithelium (RPE) cells following sub-retinal transplantation to advanced patients with SMD. A total of twelve patients will be enrolled into the study at three clinical sites, to include the Casey Eye Institute, Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health & Sciences University); the University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); and the UMDNJ – New Jersey Medical School, Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science).
Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as ten million people in the United States have photoreceptor degenerative disease. While most of these patients have Age-Related Macular Degeneration (AMD), a smaller number of patients have Stargardt’s Macular Dystrophy, a disease indication for which ACT was granted “Orphan Status” for its proposed clinical trial by the US Department of Health and Human Services earlier this year. ACT’s treatment for eye disease is sourced with human Pluripotent stem cells that are differentiated into RPE cells used to augment the patient’s existing, deteriorating RPE layer. The RPE cells are often the first to die off in SMD and AMD, which is a contributor to the patient’s loss of vision.
Several years ago ACT scientists successfully derived RPE cells from human embryonic stem cells. Later, they were able to derive them from cells developed from the Company’s proprietary “blastomere” technology that does not destroy the embryo. Subsequent studies found that the cells could restore vision in animal models of macular degeneration. In the Royal College of Surgeon (RCS) rat model, implantation of RPE cells resulted in 100% improvement in visual performance over untreated controls, without any adverse effects. The cells survived for more than 220 days and sustained extensive photoreceptor rescue. Functional rescue was also achieved in the “Stargardt’s” mouse with near-normal functional measurements recorded at more than 70 days.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2009.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Had a bit of sell on the news, but this really wasn't the big news, so we are now in an oversold position with shares available at a good price. This is a risky trade but has big upside.
Buy the rumor, sell the news. Lots of buying action tomorrow for sure.
PR with substance is good to see here. This will move things tomorrow in preparation of the revenue data.
Taking a stab here that good things are coming. Tight lips lately could be indication of news...bring us the love GCKO!
Maybe we can get good news from Sparton trip this week?
Steady buying here. These levels will not be here for long!
I like the enthusiasm!
"No doubt a significant amount of the daily shorting of GCKO stock is due to disbelieving brokerage firms betting against the reality and economic benefit of our many breakthrough mobile robot solutions. To those skeptics, that also decried the 'talkies, horseless carriages, flying machines, the telephone, the TV, the personal computer, and the Internet,' we say: Stay tuned. We are real. Our technologies are real. The family benefits are real. The markets are real. And we are in this to the realization of personal companion robot benefits for families with satisfying ROI for our now 1200+ investors," opined Spencer.